January 18, 2024
1 min watch
Save
VIDEO: ‘Promising’ monotherapy treatment for challenging to treat AML
SAN DIEGO — In this video, Akriti Jain, MD, discusses a new targeted monotherapy being used for patients with acute myeloid leukemia, tuspetinib.
Results from the APTIVATE trials were presented at ASH Annual Meeting and Exposition.
“This is something really promising for our FLT3 AML patients, which can be relapsed/refractory or the disease can be aggressive to treat,” Jain, a leukemia and myeloid disorders physician at Cleveland Clinic, said.
References:
- Daver N, et al. Abstract 162. Presented at: ASH Annual Meeting and Exhibition; Dec. 9-12, 2023; San Diego.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Jain reports no relevant financial disclosures.
Read more about